390 related articles for article (PubMed ID: 23438193)
21. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
Sukowati CH; Rosso N; Pascut D; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
BMC Gastroenterol; 2012 Nov; 12():160. PubMed ID: 23153066
[TBL] [Abstract][Full Text] [Related]
22. Cancer stem-like cell behavior in anaplastic thyroid cancer: A challenging dilemma.
Haghpanah V; Fallah P; Naderi M; Tavakoli R; Soleimani M; Larijani B
Life Sci; 2016 Feb; 146():34-9. PubMed ID: 26772823
[TBL] [Abstract][Full Text] [Related]
23. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J
Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346
[TBL] [Abstract][Full Text] [Related]
24. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Ma L; Liu T; Jin Y; Wei J; Yang Y; Zhang H
Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
[TBL] [Abstract][Full Text] [Related]
25. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
26. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
27. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
[TBL] [Abstract][Full Text] [Related]
28. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
Li G; Chen X; Wang Q; Xu Z; Zhang W; Ye L
J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):173-5. PubMed ID: 17497289
[TBL] [Abstract][Full Text] [Related]
29. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
[TBL] [Abstract][Full Text] [Related]
32. Positive Feedback Loop of OCT4 and c-JUN Expedites Cancer Stemness in Liver Cancer.
Kuo KK; Lee KT; Chen KK; Yang YH; Lin YC; Tsai MH; Wuputra K; Lee YL; Ku CC; Miyoshi H; Nakamura Y; Saito S; Wu CC; Chai CY; Eckner R; Steve Lin CL; Wang SS; Wu DC; Lin CS; Yokoyama KK
Stem Cells; 2016 Nov; 34(11):2613-2624. PubMed ID: 27341307
[TBL] [Abstract][Full Text] [Related]
33. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.
Yilmaz G; Akyol G; Cakir A; Ilhan M
Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884
[TBL] [Abstract][Full Text] [Related]
34. Detection of tumor stem cell markers in pancreatic carcinoma cell lines.
Olempska M; Eisenach PA; Ammerpohl O; Ungefroren H; Fandrich F; Kalthoff H
Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):92-7. PubMed ID: 17287174
[TBL] [Abstract][Full Text] [Related]
35. Bmi-1 is essential for the oncogenic potential in CD133(+) human laryngeal cancer cells.
Wei X; He J; Wang J; Yang X; Ma B
Tumour Biol; 2015 Nov; 36(11):8931-42. PubMed ID: 26081615
[TBL] [Abstract][Full Text] [Related]
36. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
[TBL] [Abstract][Full Text] [Related]
37. [Progress and prospects in cancer stem cell research for hepatocellular carcinoma].
Xu W; Cao L; Yin ZF
Ai Zheng; 2009 Sep; 28(9):1004-8. PubMed ID: 19728923
[TBL] [Abstract][Full Text] [Related]
38. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J
Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050
[TBL] [Abstract][Full Text] [Related]
39. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
[TBL] [Abstract][Full Text] [Related]
40. Stimulus-induced expression of the ABCG2 multidrug transporter in HepG2 hepatocarcinoma model cells involves the ERK1/2 cascade and alternative promoters.
de Boussac H; Orbán TI; Várady G; Tihanyi B; Bacquet C; Brózik A; Váradi A; Sarkadi B; Arányi T
Biochem Biophys Res Commun; 2012 Sep; 426(2):172-6. PubMed ID: 22922104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
